The NOAC benefit expanssion has heated competition of the anti-coagulant market

By the benefit expansion of the new oral anti-coagulant(NOAC), competition in the NOAC market is expected to be serious.

As the Ministry of Health and Welfare revised and issued the benefit expansion to the primary drug for the high-risk group of non-valvular atrial fibrillation patients, which will be enforced from 1 July, the NOAC market has attracted attention of the industry.

The existing...